drugset / Trial / NCT03898479

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

NCT03898479

Phase 2/3 Active not recruiting 1000 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Timeline

Start
2019-04-04
Primary completion
2027-05
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown

Indications